Venus Remedies Ltd. - Research Center
526953 VENUSREM Group (B) BSE data
Add to watchlist
| Results |
Half yearly
|
| Statement | |
| More |
Half yearly results in brief
(Rs crore)
| Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | |
|---|---|---|---|---|---|
| Sales | 329.49 | 298.12 | 171.46 | 150.90 | 146.41 |
| Operating profit | 47.30 | 25.96 | 18.37 | 24.70 | 26.65 |
| Interest | - | 10.13 | 2.13 | 10.92 | 18.41 |
| Gross profit | 52.18 | 29.08 | 18.67 | 14.93 | 11.20 |
| EPS (Rs) | 28.97 | 7.56 | -5.18 | -1.48 | -3.86 |
Half yearly
results in details
| Sep ' 21 | Sep ' 20 | Mar ' 20 | Sep ' 19 | Sep ' 18 | |
|---|---|---|---|---|---|
| Other income | 4.88 | 13.25 | 2.43 | 1.15 | 2.96 |
| Stock adjustment | 2.20 | 0.48 | -0.17 | 6.38 | -3.42 |
| Raw material | 216.97 | 197.13 | 93.46 | 77.14 | 87.43 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 20.90 | 18.40 | 18.20 | 15.59 | 14.42 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | 48.28 | 33.66 | 20.79 | - |
| Research and development expenses | - | 7.87 | 7.95 | 6.31 | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 42.13 | - | - | - | 21.33 |
| Provisions made | - | - | - | - | - |
| Depreciation | 16.83 | 16.68 | 14.45 | 16.60 | 16.45 |
| Taxation | -3.37 | 1.49 | 1.80 | 0.16 | -0.49 |
| Net profit / loss | 38.72 | 9.33 | -6.40 | -1.83 | -4.76 |
| Extra ordinary item | - | -1.58 | -8.81 | - | - |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 13.37 | 12.34 | 12.34 | 12.34 | 12.34 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 14.35 | 8.71 | 10.71 | 16.37 | 18.20 |
| GPM (%) | 15.60 | 9.34 | 10.74 | 9.82 | 7.50 |
| NPM (%) | 11.58 | 3.00 | -3.68 | -1.20 | -3.19 |
Mutual Fund Selector
Find the fund that is right for you
© 2022 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis